Stockwinners Market Radar for December 01, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:30 EST Anavex phase 2B/3 study of blarcamesine met primary and key secondary endpoints - Anavex Life Sciences "announced positive topline results from its Phase 2b/3 ANAVEX(R)2-73-AD-004 clinical trial of oral ANAVEX2-73, or blarcamesine, for the treatment of mild cognitive impairment due to Alzheimer's disease, AD, and mild AD . ANAVEX(R)2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. Next step, in light of this data, is meeting with regulatory authorities to discuss this data in the context of ongoing development with an aim to bring this therapy to patients in Europe, Asia-Pacific, and the U.S."

19:10 EST Equinix CFO sells $1.75M in common stock - In a regulatory filing, Equinix disclosed that its CFO Keith Taylor sold 2.5K share of common stock on December 1st in a total transaction size of $1.75M.

18:48 EST Babcock & Wilcox and Chart Industries to collaborate on hydrogen generation - Babcock & Wilcox (BW) has entered into an agreement with Chart Industries (GTLS) to collaborate on the further deployment of B&W's BrightLoop hydrogen generation technology, utilizing Chart's integrated hydrogen liquefaction and cryogenic carbon capture equipment and expertise. This joint solution aims to provide economic generation of low-carbon hydrogen and supplies cost-effective, transportable forms of liquid hydrogen and carbon dioxide. B&W and Chart will also work together to develop sales and marketing strategies for potential commercial hydrogen and carbon capture customers and projects.

18:32 EST Theratechnologies announces update from TH1902 study - Theratechnologies "announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Company's lead investigational peptide drug conjugate for the treatment of sortilin-expressing cancers. The Company plans to submit an amendment to its protocol to the U.S. Food and Drug Administration for approval. Theratechnologies voluntarily made the decision to pause enrollment and revisit the study design after consulting with its investigators. Efficacy results observed thus far were not convincing enough to pursue enrolling patients and did not outweigh the adverse events seen in some patients. As previously reported, these adverse events consist mainly of neuropathy and eye toxicity."

18:24 EST Crowdstrike CEO: Most companies would kill for our results - In an interview on CNBC's Mad Money, George Kurtz said customers are embracing Crowdstrike and want to buy more of its products, especially at the enterprise level. Net retention rates are near all-time highs, he noted. Lots of SMB customers are in "wait and see mode" with interest rates rising, Kurtz added. They are putting purchases on hold resulting in "elongated sales cycles."

17:59 EST Morningstar chairman sells $2.0M in common stock - In a regulatory filing, Morningstar disclosed that its Chairman Joseph Mansueto sold 8.3K shares of common stock on November 29th in a total transaction size of $2.0M.

17:30 EST Rigel Pharmaceuticals trading resumes

17:28 EST Raymond James announces $1.5B share repurchase program - The Board authorized repurchase of the company's shares of common stock in an aggregate amount of up to $1.5B. The $1.5B authorization replaces the previous repurchase authorization of $1B announced on December 2, 2021, under which approximately $800M was remaining as of December 1, 2022.

17:22 EST Dick's Sporting names Ray Sliva as EVP of Stores - DICK'S Sporting Goods "announced that Ray Sliva will join the company as Executive Vice President, Stores, effective Jan. 3, 2023. Sliva will report to President and Chief Executive Officer Lauren Hobart and serve as a key member of the company's executive leadership team. Throughout his tenure at Best Buy, Sliva held various roles in operations and human resources. Most recently, Sliva served as Best Buy's chief people officer, where he was responsible for leading all employee engagement initiatives."

17:19 EST Lockheed Martin awarded $430.93M Army contract - Lockheed Martin was awarded a $430.93M fixed-price incentive contract for full-rate production of High Mobility Artillery Rocket Systems and support services to satisfy an urgent need to support the Army and various Foreign Military Sales partners. Bids were solicited via the internet with one received. Work has an estimated completion date of December 31, 2025. FY23 missile procurement, Army funds in the amount of $209.35M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:08 EST Capcom's 'Monster Hunter Rise' out for Xbox, PlayStation in Jan 2023 - Capcom (CCOEY) said that "Monster Hunter Rise," an action role-playing game that first launched on Nintendo Switch (NTDOY) in 2021 and then on PC in 2022, will be coming to Xbox Series X/S (MSFT), Xbox One, Windows, Game Pass, PS5 (SONY, and PS4 on January 20, 2023. The "Sunbreak" expansion to the game launches for these new platforms in Spring 2023, the company said. Reference Link

17:04 EST Maverix Metals granted interim order for transaction with Triple Flag - Maverix Metals announced that on November 30, the Ontario Superior Court of Justice has granted an interim order in connection with the previously announced statutory plan of arrangement under Section 192 of the Canada Business Corporations Act, pursuant to which, among other things and subject to the satisfaction or waiver of all applicable conditions precedent, Triple Flag Precious Metals Corp. will acquire all of the issued and outstanding common shares of Maverix. The interim order authorizes the calling and holding of a special meeting of the Maverix shareholders to be held on January 12, 2023, the granting of dissent rights to the registered Maverix shareholders and other matters relating to the conduct of the special meeting.

16:48 EST Patria Investments acquires Igah Ventures in Latin America - Patria Investments launched a new Venture Capital strategy, anchored by the acquisition of Igah Ventures. Igah's business complements Patria's existing Private Equity and Growth Equity strategies, which are focused on relatively mature companies, by adding investment expertise in startups and early-stage companies. Igah Ventures has been operating since 2013 with three funds raised from local and international investors, having contributed to startups such as Infracommerce, Contabilizei, Unico, Avenue and Conexa Saude. Overall, the investment management company currently has $320M in total AUM and about $140M in fee earning AUM. Patria has acquired 100% of Igah Ventures, with the closing of the transaction also now completed. Consideration structure consists of an upfront cash payment, equity to be paid in the form of PAX Class A shares over the course of the next twelve months, as well as an earnout component contingent on meeting certain fundraising targets. Specific financial terms of the transaction are not being disclosed. Igah is expected to be profitable on an FRE basis looking forward, with the ability to scale with the raising of the upcoming fourth vintage fund.

16:36 EST Asana falls 12% to $15.94 after Q3 results and guidance

16:35 EST Aterian reports Cyber Monday sales up 60% from last year - Aterian announced that its revenue generated on Cyber Monday, November 28, was up approximately 60% compared to last year's Cyber Monday. The company noted the strength was broad based and included strong sales in many of the company's brands and products.

16:33 EST Mobiquity Technologies receives noncompliance notification from Nasdaq - Mobiquity Technologies announced that it received a deficiency notification from the Listing Qualifications Department of Nasdaq notifying the company of its noncompliance with the Nasdaq Listing Rule 5250 due to its failure to file its Form 10-Q for the period ended September 30. Under Nasdaq's Rules, the company has 60 calendar days to submit a plan to regain compliance. It is anticipated that the Form 10-Q will be filed by the company on or about December 9, 2022. As more fully described in the recently filed Form 8-K, the Audit Committee of the company and its prior independent public accountant, determined that it is necessary to file Form 10-K/A No. 2 to amend various financial information in the company's annual report with respect to the audited financial statements for the fiscal years ending December 31, 2021 and 2020 and the quarterly information pertaining to those fiscal years. The aforementioned amended annual report caused the company to be late with the filing of its Form 10-Q for the quarter ended September 30. On November 28, the Audit Committee of Mobiquity Technologies, Inc.'s board of directors determined that its Form 10-K/A filed on May 23, which included the audited consolidated financial statements for the years ended December 31, 2020 and 2021, could no longer be relied upon because the year ended December 31, 2020 overstated its net loss by approximately $3,287,000 primarily as a result of the erroneous recording of various non-cash expenses. The company has notified its prior and current independent auditors of the need to file a Form 10-K/A No. 2 with new audited consolidated financial statements for the years ended December 31, 2020 and 2021 to correct the errors that resulted in an overstatement of the net loss in both years. It is the intention of the company that the Form 10-K/A No. 2 will contain in the notes to consolidated financial statements condensed quarterly balance sheets, statements of operation and statements of cash flows to correct quarterly information for the periods ended March 31, 2021 and 2020, June 30, 2021 and 2020 and September 30, 2021 and 2020. Accordingly, the quarterly reports for these periods cannot be relied upon and will be superseded and/or supplemented by the information contained in the aforementioned Form 10-K/A No. 2.

16:32 EST Fisker to take 'immediate' action to address 'false' claims by Fuzzy Panda - Fisker has responded to a report published by Fuzzy Panda Research. On Dec. 1, 2022, Fisker issued a cease-and-desist letter to the firm, which announced a short position in Fisker stock at the same time it released a purported assessment containing numerous false and misleading allegations about Fisker's business operations and its relationship with manufacturing partner Magna. Fisker said: "Fisker Inc. does not have a bank guarantee with Magna, and Fisker owns the intellectual property for the Fisker Ocean platform. The Ocean platform does not have 80 percent carryover parts from any other platform." Fisker said it intends to take immediate and aggressive action to address the "false and misleading" claims made by Fuzzy Panda Research.

16:31 EST Accuray to eliminate about 4.5% of workforce in cost saving initiative - In a regulatory filing, Accuray reported that On December 1, the company informed affected employees of a cost saving initiative designed to reduce operating costs through the elimination of approximately 4.5% of its global workforce. The company expects to substantially complete the cost saving initiative in the second quarter of fiscal 2023. The company estimates the total cost of this initiative to be approximately $2.0M, which is expected to be recorded in the second quarter of fiscal 2023.

16:28 EST Triumph Bancorp rebrands to Triumph Financial, changes symbol - Triumph Bancorp announced the completion of a rebranding effort, including a change of the company name to Triumph Financial. Prior to the market open on December 2, the company's common stock will begin trading on Nasdaq under the ticker symbol (TFIN). This will replace the company's current ticker symbol for its common stock (TBK), which has been used since its initial public offering in November 2014. In addition to the Triumph Financial rebranding, the brands Triumph Business Capital, Triumph Insurance Group and Triumph Commercial Finance have consolidated factoring, insurance and banking services for the transportation industry to go to market as a single brand - Triumph.

16:22 EST Guild Mortgage acquires Inlanta Mortgage, terms not disclosed - Guild Mortgage has acquired Inlanta Mortgage, Inc., a Wisconsin-based independent lender serving borrowers in 27 states. "Inlanta is a natural fit because of its almost 30-year history, strong management team, employee-oriented culture and dedication to customer service," Guild CEO Mary Ann McGarry said. "Its culture and values mirror what we've been building at Guild for more than 60 years. Together we will use our combined strengths to drive further growth throughout the Midwest."

16:21 EST Solid Biosciences stockholders approve acquisition of AavantiBio - Solid Biosciences announced the results of the special meeting of the stockholders held on December 1. At the special meeting, Solid's stockholders voted in favor of all proposals, including the proposal to issue shares of Solid's common stock to stockholders of AavantiBio in connection with the acquisition of AavantiBio pursuant to the agreement and plan of merger dated September 29 and to certain institutional investors in connection with a concurrent $75M private placement. AavantiBio is a privately held gene therapy company focused on transforming the lives of patients with Friedreich's ataxia and rare cardiomyopathies. Subject to the satisfaction or waiver of the other customary closing conditions, the closings of the merger agreement and the private placement are anticipated to take place on or around Friday, December 2. The combined company will focus on advancing a portfolio of neuromuscular and cardiac programs, led by SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne. Additional pipeline programs include AVB-202, a gene transfer candidate for the treatment of Friedreich's ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases.

16:18 EST Ventyx Biosciences doses first patient in VTX958 trial - Ventyx Biosciences announced that the first patient has been dosed in a Phase 2 trial of its selective, allosteric TYK2 inhibitor VTX958 for the treatment of moderate to severe plaque psoriasis.

16:16 EST Unum Group announces $200M share repurchase authorization - Unum Group announced that its board of directors has approved a share repurchase program authorizing the company to repurchase up to $200M of its common stock from time to time from January 1, 2023 through December 31, 2023. This program follows the company's current share repurchase program, which expires on December 31, 2022.

16:14 EST Sterling Construction to divest 50% stake in Myers & Sons Construction - On November 30, 2022, Sterling Infrastructure entered into an agreement and sold the company's 50% ownership interest in its partnership with Myers & Sons Construction L.P. for $18M in cash. In accordance with the Agreement's payment terms, the company is to receive $12M by early 2023 and a series of three $2M payments due by various dates in 2023, 2025, and 2027. The divestiture is consistent with the company's strategy of reducing its portfolio of low-bid heavy highway projects in order to increase the company's margins and of focusing on its strategic geographies. "This transaction enables us to continue advancing in areas aligned with our strategic vision," stated Joe Cutillo, Sterling's Chief Executive Officer. "Myers operations are largely outside our primary areas of focus with respect to project type and geography. The proceeds from this divestiture further enhance our future investment in strategic growth areas."

16:12 EST ICF International awarded $26M recompete contract - An organization that administers programs on behalf of the Federal Communications Commission recently awarded ICF a $26M recompete contract to accelerate the modernization of its enterprise-wide mission-critical business systems. The contract, which was awarded in the third quarter of 2022, has a term of three years, including a one-year base and two one-year options. ICF will provide digital modernization advisory and governance support, as well as rapidly deployed operations, maintenance, development and enhancement support, that will advance the use of high-speed connectivity in communities across the nation.

16:07 EST Marvell reports Q3 adjusted gross margin 64%

16:04 EST Maravai Lifesciences announces plans for William Martin to become CEO in 2023 - Maravai LifeSciences (MRVI) announced plans for William Martin, III to serve as president of Maravai's Biologics Safety Testing Segment beginning December 5 and expects that Martin will assume the role of CEO of Maravai LifeSciences on July 27, 2023. Christine Dolan, the current COO of Maravai's Biologics Safety Testing Segment, will continue to serve in that role and will report to Martin. Carl Hull, Maravai's co-founder, will continue to serve as Maravai's executive chairman and interim CEO. Maravai had previously announced the appointment of Martin to the role of CEO, and his subsequent placement on a paid leave of absence as a result of a lawsuit claiming violation of a noncompetition agreement filed by two of Martin's former employers, subsidiaries of Danaher (DHR), and one of their affiliates. Martin, Maravai, and the Danaher entities have reached a confidential settlement pursuant to which Maravai and Martin have agreed to limit Martin's responsibilities for Maravai and preclude his involvement in Maravai's Nucleic Acid Production Segment through July 26, 2023. The parties also agreed to voluntarily dismiss the lawsuit.

16:00 EST Marsh McLennan Agency acquires McDonald Zaring Insurance, terms not disclosed - Marsh McLennan Agency announced the acquisition of McDonald Zaring Insurance, a full-service agency located in Walla Walla, Washington. Terms of the acquisition were not disclosed. "McDonald Zaring Insurance prides itself on its extensive experience and deep client relationships, aligning perfectly with MMA's approach to helping clients achieve their goals and create a limitless future," commented Kyle Lingscheit, CEO of MMA's Northwest region. "We look forward to the collaboration and innovation to come as we welcome MZI to the MMA team and further bolster our presence in the region."

14:45 EST Palisade Bio regains compliance with Nasdaq listing requirements - Palisade Bio announced that on December 1, 2022, it received notice from The Nasdaq Stock Market LLC that it has regained compliance with the Nasdaq Listing Rules for continued listing on The Nasdaq Capital Market.

13:53 EST Baxter sees some recessionary risk in 2023 - Says hospital capital environment in 2023 an "important variable" for the company. Says dimensions "somewhat limited" as far as company's ability to raise prices until contracts expire at the end of 2024. Says can't raise prices to offset higher costs until end of 2024. Says close to being in position to submit new pump to FDA, which is an "important variable" for 2023. Comments taken from Evercore ISI Healthconx Conference.

13:34 EST Royal Caribbean International says bookings records set for third time in 2022 - Royal Caribbean International, owned by Royal Caribbean Group, announced it has set a "new bookings records yet again." The cruise line division stated: "This Black Friday was the cruise line's single largest booking day in its 53-year history, which marked the third time the record was broken in 2022 and the peak of what is now the brand's highest volume booking week. The strong demand and performance demonstrated by the two latest records come on the heels of the first look at the world's best family vacation, Icon of the Seas, and the record-breaking day reported when the highly anticipated ship opened for bookings 15 months ahead of its January 2024 debut."

13:25 EST Subaru of America reports November sales up 51.7% to 50,138 vehicles - Subaru of America reported 50,138 vehicle sales for November, a 51.7% increase compared with November 2021 sales of 33,045. The automaker also reported year-to-date sales of 499,821, a 6.2% decrease compared with the same period in 2021.

13:04 EST Rigel Pharmaceuticals trading halted, news pending

13:00 EST RemeGen granted orphan status for pancreatic cancer treatment - The FDA granted RemeGen orphan status for its treatment of pancreatic cancer. Reference Link

12:49 EST Honda reports November U.S. sales down 6.1% to 79,862 vehicles - American Honda November sales totaled nearly 80,000 units, down 6.1% y/y. Honda crossovers lead the way with all-new CR-V sales of almost 20,000 units and all-new HR-V over 9,000 units, logging its best month since June, the company said in a statement. The all-new Pilot goes on-sale in December and is already generating strong pre-sale activity, Honda added.

12:11 EST Nexstar exec Alford sells 5,000 common shares - In a regulatory filing, Nexstar Media broadcasting president Andrew Alford disclosed the sale of 5,000 common shares of the company on November 29 at a price of $187.5685 per share.

12:00 EST Farfetch falls -20.2% - Farfetch is down -20.2%, or -$1.72 to $6.78.

12:00 EST AMC Entertainment rises 12.8% - AMC Entertainment is up 12.8%, or 93c to $8.15.

12:00 EST REX American Resources rises 17.7% - REX American Resources is up 17.7%, or $5.22 to $34.73.

11:27 EST AMC Entertainment trading resumes

10:49 EST Hoth Therapeutics announces submission of IND application for HT-001 - Hoth Therapeutics announced that it submitted an Investigational New Drug, or IND, application to the U.S. Food and Drug Administration on December 1. "The IND application supports a proposed indication of treatment for rash and skin disorders associated with epidermal growth factor receptor inhibitor therapy... The IND Submission is being submitted via the 505(b)(2) development pathway, in which Hoth Therapeutics intends to rely on information not obtained through right of reference in order to reduce the nonclinical and clinical program and expedite time to NDA submission. During the pre-IND meeting with the FDA, Hoth Therapeutics plans to discuss the overall proposed drug development program for HT-001 including requirements for nonclinical, clinical pharmacology, clinical, and chemistry, manufacturing, controls. Hoth also plans to present clinical trial designs for the IND-opening, phase 2a dose ranging study as well as a proposed follow-up phase 2b safety and efficacy dose extension study; both studies will be conducted in cancer patients receiving EGFR inhibitor therapy. The FDA will review this application and determine the acceptability of the data before Hoth begins this first clinical trial, which could be as early as Q1 2023. It is possible that the FDA will require additional information," the company stated.

10:42 EST Vuzix says Vuzix Blade glasses used in cardiac rehabilitation treatment - Vuzix Corporation (VUZI) announced that Kyocera (KYOCF) has developed a cardiac rehabilitation treatment in collaboration with Tokyo Medical Dental University that employs Vuzix Blade smart glasses. The system, developed in collaboration with Tomoyuki Umemoto and his colleagues in the Department of Cardiovascular Medicine at Tokyo Medical and Dental University, combines a Kyocera bone conduction headset with biometric sensing, Vuzix Blade smart glasses, and a small electrocardiograph. Patients undergoing cardiac rehabilitation therapy wear the headset and ECG, while physicians wear the smart glasses to monitor the biometric data. Abnormalities in pulse, oxygen saturation, and ECG can be detected visually and audibly, allowing the therapist to assist the patient with both hands free. Customized software displays various biological information on the smart glasses so that it can be grasped in an integrated manner.

10:38 EST Starwood Waypoint Homes trading resumes

10:28 EST Starwood Waypoint Homes trading halted, volatility trading pause

10:02 EST Goodyear Tire, Nascar enter new multiyear agreement for tires - The Goodyear Tire & Rubber Company and NASCAR announced a new multi-year agreement renewing Goodyear's position as the exclusive tire for NASCAR's top three national series. The agreement continues Goodyear's designation as the "Official Tire of NASCAR," as well as the title sponsor of the annual Goodyear 400, NASCAR's Official Throwback Weekend Cup Series race at Darlington Raceway.

10:00 EST One Gas falls -13.5% - One Gas is down -13.5%, or -$11.75 to $75.20.

10:00 EST Atento rises 9.5% - Atento is up 9.5%, or 54c to $6.18.

10:00 EST Yext rises 19.7% - Yext is up 19.7%, or $1.05 to $6.38.

09:49 EST Blink Charging deploys 50 EV charging stations at Midtown Union in Atlanta - Blink Charging announced it has installed 50 EV charging stations through SemaConnect at the Granite Properties development, Midtown Union in Atlanta, Georgia, a new, transformative, mixed-use development serving offices, retail and multifamily. The EV charging stations are split between Midtown Union's north and south parking decks and will serve the office customers, including Invesco's new global HQ, residents of the Mira at Midtown Union, and soon to open retailers.

09:47 EST Designer Brands falls -12.9% - Designer Brands is down -12.9%, or -$1.97 to $13.33.

09:47 EST Atento rises 9.1% - Atento is up 9.1%, or 51c to $6.15.

09:47 EST PVH Corp. rises 10.5% - PVH Corp. is up 10.5%, or $7.03 to $74.21.

09:41 EST Pacifico Acquisition Corp trading resumes

09:32 EST Amgen presents new Phase 1 AMG 133 data at WCIRDC 2022 - Amgen announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor antagonist and glucagon-like peptide-1 receptor agonist molecule. This first-in-human study was designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of AMG 133 in people with obesity and without diabetes. These data will be presented as part of an oral presentation on Saturday, Dec. 3 at the 20th World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease Hybrid Conference. Participants were randomized to receive subcutaneous AMG 133 or placebo either as a single ascending dose or multiple ascending doses. The MAD cohorts showed mean percent changes in body weight, ranging from -7.2% at the lowest dose, to -14.5% at the highest dose by day 85. A substantial degree of weight loss was maintained beyond the treatment period, which will be shared as part of the oral presentation. Most treatment emergent adverse events were mild and transient. The majority of the TEAEs were GI-related with the most common being nausea and vomiting, most events resolved within 48 hours. Based on these data, a Phase 2 trial will be initiated early next year to further study the attributes of this molecule.

09:28 EST Harte Hanks completes acquisition of InsideOut Solutions - Harte Hanks announced that it has completed the acquisition of InsideOut Solutions, an inside sales optimization firm. InsideOut offers inbound and outbound sales outsourcing and experimentation services for partners globally. The combined organizations will begin operations as Harte Hanks on December 1, with 136 employees joining the Harte Hanks team. Harte Hanks also adds a seventh location to its North American offices with the acquisition of InsideOut's 7,500-square-foot headquarter facility based in St. Petersburg, Florida.

09:22 EST Domo joins Amazon SageMaker Ready Program - Domo announced it has joined the Amazon SageMaker Ready Program. This designation helps customers discover partner software solutions that are validated by Amazon Web Services Partner Solutions Architects to integrate with Amazon SageMaker.

09:19 EST Amazon announces Yahoo selects AWS as preferred cloud provider - At AWS re:Invent, Amazon Web Services, an Amazon company, announced that Yahoo has selected AWS as its preferred public cloud provider for its advertising technology business Yahoo Ad Tech. Building on its longtime relationship with AWS, Yahoo Ad Tech is migrating all of its advertising technology workloads-including its media-buying and supply-side platforms, analytics, and identity solutions and products-from its on-premises data centers to AWS. The migration is part of the business's ongoing digital transformation strategy to reduce IT infrastructure costs, transform its advertising business operations, and develop more tailored and immersive solutions to help brands connect with their audiences.

09:18 EST MicroVision to acquire Ibeo Automotive Systems assets for up to EUR 15M - MicroVision announced the signing of an agreement to acquire certain assets from Hamburg, Germany-based, Ibeo Automotive Systems GmbH, for up to 15 million euros. The acquisition combines MAVIN lidar with Ibeo perception software features into the MicroVision ASIC for automotive OEMs. In addition, this acquisition expands MicroVision's multi-market strategy focusing on industrial, smart infrastructure, robotics, and commercial vehicle segments with Ibeo's flash-based sensor. The combined company is expected to have revenue streams from existing and new product lines ranging from software, Ibeo's flash-based lidar and MicroVision's scanning lidar sensor, as well as other combinations of hardware with perception software solutions. Ibeo Automotive Systems Gmbh is a well-established lidar hardware and software provider with the team that developed and launched the SCALA sensor into serial production with a Tier 1 that is today used by premium OEMs like Audi, Mercedes and Stellantis and software solutions used by BMW and VW, to name a few. The experienced Ibeo team has also innovated in OEM qualified software including auto-annotation, validation, and perception solutions. They have also done advanced development in software required for autonomous driving. Ibeo has a very impressive team, and the combined company has a common DNA in innovation and execution, with more than 700 patents globally. Under the terms of the asset purchase agreement, MicroVision will acquire certain Ibeo assets, IP, and teams to operate within the MicroVision organization as of the closing date. The acquisition includes highly talented and experienced engineering teams, revenue-producing hardware and software businesses, and automotive-focused and multi-market business development and sales professionals. The closing of the acquisition, expected to occur during the first half of 2023, is subject to regulatory clearance from the German Ministry of Economics and Climate Protection.

09:16 EST American Lithium announces updated MRE for TLC project - American Lithium announces an updated Mineral Resource Estimate, MRE, that significantly increases the contained lithium resources for the Tonopah Lithium Claims, TLC, project located in the Esmerelda lithium district northwest of Tonopah, Nevada. Simon Clarke, CEO of American Lithium states, "We are very pleased with the results of our 2022 drill programs culminating in a much larger mineral resource at TLC which underlines our position as one of the largest lithium projects in North America. In addition, the higher-grade shallow lithium mineralization identified in our core Measured resource area provides focus for early production that should have a positive impact on the economic potential of TLC. This will be reflected in a robust maiden PEA, which we are in the process of completing in conjunction with DRA Global, and should help fast-track the Project's move through feasibility"

09:15 EST Allied Esports Entertainment changes name, expands focus after review process - Allied Gaming & Entertainment, Inc. (AGAE), formerly known as Allied Esports Entertainment (AESE), announced the conclusion of its previously announced strategic review process. The strategic review was overseen by the company's board of directors and included the assistance of The Benchmark Company, which served as the company's exclusive financial advisor in connection with a potential business combination transaction. After carefully considering possible alternatives, the company has determined that its shareholders' interests will be best served by restructuring its existing esports business operations and expanding its focus to include a broader array of entertainment and gaming products and services in lieu of seeking a single business combination transaction. In alignment with the announcement, the company changed its corporate name and rebranded to "Allied Gaming & Entertainment Inc." The company's common stock continues to be publicly traded on the Nasdaq Capital Market under the new ticker symbol (AGAE). In addition, the company has appointed Robert Proctor as the new CEO of Allied Esports International, a 100% owned subsidiary of the company, to lead the restructuring of the company's esports business.

09:14 EST LeasePlan USA, Wheels Donlen complete combination - LeasePlan USA and Wheels Donlen announced the completion of their previously announced combination to create a unified fleet management business. Athene Holding served as the lead investor in the transaction and is the majority shareholder of the newly combined company. Combining LeasePlan USA and Wheels Donlen creates a corporate mobility solutions leader, with greater scale, enhanced investment capacity and differentiated capabilities to better serve clients globally. The combined company will be led by CEO Shlomo Crandus. Matt Dyer, previously CEO of LeasePlan USA, will serve as its President and as a board member of the combined company. Jim Belardi, CEO of Athene Holding Ltd., said, "For Athene, this transaction follows our longstanding strategy to invest in businesses with strong fundamentals, underwriting and direct origination capabilities. We are committed to the growing fleet management market and the leading role that the combined Wheels Donlen LeasePlan will play in serving the fast-evolving fleet needs. With the closing of this transaction, we look forward to more opportunities to invest in the combined company and equipping the business for long-term success."

09:11 EST Castor Maritime announces deliveries of two containership vessels - Castor Maritime announces the deliveries of two vessels. On November 23, and on November 30, 2022, Castor took delivery of M/V Ariana A and M/V Gabriela A, respectively, both of which are 2005 German-built 2700 TEU containership vessels. We had agreed to acquire these vessels as previously announced at the time of the earnings release for the results of the third quarter of 2022. The M/V Ariana A is currently employed under a time charter contract with minimum remaining duration of about four months at a minimum gross daily hire of $23,250. The M/V Gabriela A is currently employed under a time charter contract with minimum duration of about sixteen months at a minimum gross daily hire of $26,350. Both vessel acquisitions were financed with cash on hand and the net proceeds from a new senior term loan facility. The Company also announces the closing of a $22.5 million senior term loan facility by two of its container vessel ship-owning subsidiaries, with an Asian financial institution secured by its two containership vessels.

09:10 EST EnWave announces CFO Henriques to leave, Murray to succeed - EnWave announced that Dylan Murray has been appointed as Chief Financial Officer, CFO, of the Company, effective December 1, 2022. Murray is replacing Dan Henriques, the current CFO, who will be leaving to pursue another professional opportunity. Murray is a Chartered Professional Accountant and began his career with Ernst & Young. He brings over ten years of progressive financial leadership to the Company.

09:08 EST MICT completes acquisition of operating business, assets of Tingo - MICT (MICT) has completed the previously announced acquisition of 100% of the operating business and assets of Tingo (TMNA), via its purchase of Tingo Mobile. As the consideration for the acquisition, MICT is issuing 19.9% of its common stock to Tingo, together with Series A Preferred Stock and Series B Preferred Stock, each of which are convertible into shares of MICT's common stock upon certain conditions being satisfied. Darren Mercer, Chief Executive Officer of MICT, commented: "When we embarked in 2021 on our search for value accretive business acquisitions in the fintech sector, which would either provide access to new markets for our current suite of products or with new platforms to introduce into our existing markets, we never dreamt of finding an opportunity as valuable as this and with such a strong synergistic fit.. We firmly believe we have acquired one of the world's most exciting agri-fintech and fintech businesses. As reported in Tingo's Q3 results, Tingo Mobile is already highly profitable and growing strongly. Within the past few weeks, Tingo Mobile has delivered a number of major trade deals, which not only are expected to result in a more than tripling of current customer numbers, but also marks the commencement of its global expansion."

09:06 EST Arcimoto announces five new rental partners - Arcimoto announced that FUVs are now available to rent in Las Vegas, Los Angeles, Morro Bay, Calif., Orlando, Fla., and Amelia Island, Fla. "Our largest expansion of our rental program to date, these new rental locations bring clean, sustainable, thrilling rental options to top tourist destinations Las Vegas, Los Angeles, and Orlando, as well as to the pristine coastal communities of Morro Bay, and Amelia Island," said Lynn Yeager, Arcimoto Chief Experience Officer. "We're proud to partner with these outstanding organizations, and look forward to adding additional rental locations next year."

09:04 EST AMD, Viettel collaborate on 5G mobile network expansion - AMD and Viettel High Tech announced the successful completion of a 5G mobile network field trial deployment conducted by Viettel and powered by AMD Xilinx Zynq UltraScale+ MPSoC devices. Designed to meet the growing capacity and performance requirements of mobile users globally, the Viettel 5G mobile network is expected to be completed by the end of 2022. "5G provides new opportunities to offer higher levels of performance, power efficiency and new services along with increased reliability required to meet the growing data demands of cellular networks," said Yousef Khalilollahi, corporate vice president of APAC sales, Adaptive and Embedded Computing Group, AMD. "We are proud of our close collaboration with Viettel and remain focused on enabling its mobile network to deliver the optimal end-user experience as well as the flexibility to evolve and grow as Viettel's user base and required bandwidth continue to increase globally."

09:04 EST Victory Square portfolio company Hydreight begins trading on TSXV - Victory Square Technologies announces that its portfolio company, Hydreight Technologies has received final approval for its qualifying transaction as principally described in its filing statement dated November 10, 2022, from the TSX Venture Exchange and its common shares have commenced trading on the TSXV under the symbol 'NURS' effective at market open on December 1, 2022.

09:02 EST HeartSciences, Rutgers University announce multi-year collaboration - Heart Test Laboratories announced that it has entered into a multi-year collaboration agreement with Rutgers University. HeartSciences and Rutgers will collaborate to develop AI-based ECG algorithms, which are expected to accelerate HeartSciences' product development pipeline and further expand the clinical value of an ECG for low-cost detection of heart disease. These collaboration efforts will be focused on leveraging the extensive clinical data compiled at Rutgers. Andrew Simpson, CEO of HeartSciences, stated, "We are excited and honored to enter a collaboration with Dr. Sengupta and Rutgers University. Dr. Sengupta is a globally respected figure in the field of cardiology, including the application of technology to accelerate innovation in the field of cardiology. We have worked with Dr. Sengupta and his team in the past, with multiple published studies using MyoVista technology. This collaboration formalizes a multi-year arrangement with Rutgers, which we believe will significantly accelerate our product development pipeline of new ECG algorithms for front-line physicians and other healthcare providers. There are millions of ECGs conducted every week and this collaboration reaffirms HeartSciences' position at the leading edge of bringing new clinical capabilities to the ECG."

09:01 EST Enovis receives FDA approval of patient specific instrument for STAR Ankle - Enovis announced that the U.S. Food and Drug Administration, FDA, has approved the STAR Patient Specific Instrumentation, STAR PSI System, for use with the Company's STAR total ankle replacement system. "Today is an exciting day for our customers and patients," said Gary Justak, President of Enovis Foot & Ankle. "We acquired the STAR Ankle just two years ago, and the FDA approval of STAR PSI is just one example of our team's commitment and investment to taking this best-in-class product to the level it deserves. Surgeons now have leading pre-operative planning and cutting guides, that when paired with years of proven, clinical data, set STAR Ankle up for a brilliant future." The product is entering Early Product Surveillance in December with plans to fully launch by the end of March 2023.

08:54 EST Ford announces GBP 125M investment in Halewood Plant, GBP 24M in E:PriME center - Ford has invested a further GBP 125M in its Halewood Plant, on Merseyside, increasing capacity by 70% and GBP 24M in the supporting E:PriME product development center. This announcement takes total investment in enabling Halewood's transformation to an EV component plant to almost GBP 380M. Halewood's new power unit capacity, raised from 230,000 to 420,000 a year, a 70% increase, also means that 70% of the 600,000 EVs, which Ford will sell in Europe a year by 2026, will be powered by the Halewood-produced technology. Ford's EV push in Europe supports the acceleration of the company's global plan for two million annual production of EVs in the same 2026 time frame. Halewood will deliver to the vehicles' assembly lines at Ford Otosan plants in Romania and Turkey, making up a significant share of Ford UK's annual export value from the Merseyside plant, as well as Dagenham - currently worth GBP 2.1B annually.

08:46 EST Spark Networks names Board Vice Chair Chelsea Grayson as Interim CEO - Spark Networks appointed current Board of Directors Vice Chair Chelsea Grayson as interim CEO. Eric Eichmann has stepped down to spend more time with family and explore future opportunities. Grayson is the former CEO of True Religion, a designer jeans and clothing company, as well as clothing company American Apparel.

08:46 EST Eloxx Pharmaceuticals announces 1-for-40 reverse stock split - Eloxx Pharmaceuticals announced that its Board of Directors has approved a 1-for-40 reverse stock split of the Company's common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time today, December 1, 2022, after close of trading on The Nasdaq Capital Market. The Company's common stock is expected to commence trading on a split-adjusted basis when the markets open on December 2, 2022 under the existing trading symbol "ELOX." The new CUSIP number for the Company's common stock following the reverse stock split will be 29014R202. The primary goal of the reverse stock split is to increase the per share market price of the Company's common stock to meet the minimum per share bid price requirement for continued listing on The Nasdaq Capital Market. The reverse stock split was approved by the Company's stockholders at a special meeting of stockholders held on November 30, 2022. On November 30, 2022, following the special meeting, the Company's Board of Directors approved the reverse stock split at the ratio of 1-for-40.

08:43 EST VICI Properties to buy 49.9% interest in MGM joint venture from BREIT for $1.27B - Blackstone Real Estate Income Trust, or BREIT, and VICI Properties (VICI) announced jointly that they have entered into a definitive agreement in which VICI, currently owner of a 50.1% interest in the joint venture that owns MGM Grand Las Vegas and Mandalay Bay Resort, will acquire BREIT's 49.9% interest in the joint venture for cash consideration of approximately $1.27B and VICI's assumption of BREIT's pro-rata share of the existing property-level debt. The property-level debt has a principal balance of $3B, matures in 2032, and bears interest at a fixed rate of 3.558% per annum through March 2030. The properties, situated at the south end of the Las Vegas Strip in Las Vegas, Nevada, are subject to an existing triple-net lease agreement between the joint venture and MGM Resorts (MGM). The lease will generate annual rent of approximately $310less than upon the commencement of the next rental escalation on March 1, 2023.

08:39 EST KULR adds suite of battery safety, testing solutions with new license - KULR Technology (KULR) announced it has achieved operational readiness for its Fractional Thermal Runaway Calorimeter, FTRC, within its suite of battery safety and thermal management solutions after finalizing a commercial licensing agreement with the National Aeronautics and Space Administration, NASA, for the agency's patent-pending FTRC solution. Following a one-year trial license from NASA, KULR's new commercial license allows FTRC to be utilized by commercial-leaning companies, such as leading aerospace company Lockheed Martin (LMT). "FTRC is a key part of KULR's holistic methodology for the design of safe battery systems and amplifies the Company's mission of providing commercially applicable solutions that support the electrification of the circular economy," said Dr. William Walker CTO of KULR Technology Group. "It is humbling to see a technology that I co-invented during my tenure at NASA become a licensed product in private industry and I am excited to support our customers with this new service offering. Fractional calorimetry has certainly changed the way we understand thermal runaway and I cannot wait to see what else is revealed to the industry as we continue our explorative studies internally on thermal runaway behavior."

08:38 EST ON Semiconductor divests Japan facility to JS Foundry K.K. - ON Semiconductor announced the completion of the sale of its Niigata, Japan facility to JS Foundry K.K. The divestiture aligns with onsemi's fab-liter strategy to expand gross margin and improve predictably of its financial results by reducing fixed cost footprint. JS Foundry K.K. was founded through a partnership between Mercuria Investment and Sangyo Sosei Advisory Corporation.

08:37 EST UGI Corporation appoints Robert Beard as COO - UGI Corporation announced that Robert Beard has been appointed COO reporting to UGI's president and CEO, Roger Perreault, effective immediately. In his new role, Beard will be responsible for oversight of UGI's Global LPG line of business in addition to the Natural Gas line of business, which he led previously.

08:36 EST Tantech Holdings regains compliance with NASDAQ minimum bid price requirement - Tantech Holdings received notification from Nasdaq confirming the company has regained compliance with NASDAQ's minimum bid price requirement and the matter is now closed.

08:35 EST Sellas announces results from preclinical in vivo study of GFH009 - SELLAS Life Sciences announced results from a preclinical in vivo study for its highly selective CDK9 inhibitor, GFH009, that demonstrate robust inhibition of tumor growth in a mouse xenograft model of small cell lung cancer, SCLC. GFH009 was tested against NCI-H209 SCL xenografts in athymic nude mice in four treatment groups of eight mice each consisting of GFH009 alone, olaparib alone, a combined regimen of GFH009 and olaparib, and a vehicle control. GFH009 treated mice exhibited a 40.4% decrease in mean tumor growth compared to the control group in this very aggressive cancer model which had a tenfold increase in average tumor volume over 20 days. Strongest effects were observed with GFH009 in combination with olaparib, with mean tumor growth decreased by 72.3%. Treatment with olaparib alone resulted in a 30.2% mean decrease in tumor growth. "We are looking forward to expanding use of GFH009 into solid cancers and these results indicate CDK9 can be an actionable target not only in the apoptotic pathway but also the DNA damage response pathway," said Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS. "This opens up additional avenues for the use of GFH009 in an expanding array of difficult to treat cancers based on their genomic and proteomic traits, moving another step towards truly personalized medicine."

08:35 EST Honeywell and Nexceris partner for EV battery cell safety - Honeywell is expanding its strategic alliance with Nexceris, developer of Li-ion Tamer lithium-ion gas detection solutions, to help make electric vehicles - EVs - safer. Honeywell and Nexceris will co-develop sensor based solutions to help prevent conditions leading to thermal runaway in EV batteries, a phenomenon that causes extremely high temperatures within the battery cell and can result in a fire. The companies will collaborate with leading global vehicle manufacturers to deliver advanced gas detection solutions in EV battery packs to allow for early intervention, helping avoid costly property damage and safety issues.

08:33 EST Compass announces first patient dosed in Phase 1b CTX-471 combination trial - Compass Therapeutics (CMPX) announced that the first patient has been dosed in the Phase 1b study of CTX-471 in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with advanced solid tumors. CTX-471 is supplied by Compass, which is also the sponsor of this study, and KEYTRUDA will be supplied by Merck (MRK) under a clinical collaboration and supply agreement between the companies. This study enrolls patients with metastatic or locally advanced non-small cell lung cancer, melanoma, small cell lung cancer, mesothelioma, and head and neck cancer that have progressed after treatment with a checkpoint inhibitor. CTX-471 has completed a Phase 1 dose escalation and cohort expansion study, where it was shown to be well-tolerated. The Phase 1b monotherapy study is fully enrolled and ongoing. In this study, CTX-471 has been evaluated as a monotherapy treatment in patients with advanced solid tumors who received at least one checkpoint inhibitor post progression.

08:32 EST Newtek receives approval from OCC to acquire National Bank of New York City - Newtek Business Services announced that it has received conditional approval from Office of the Comptroller of the Currency to complete its acquisition of the National Bank of New York City. Newtek announced last week that it received approval from the Federal Reserve to become a bank holding company and a financial holding company by acquiring NBNYC. Newtek expects the Acquisition to close in January 2023, subject to completion or waiver of the remaining closing conditions. Upon the close of the Acquisition, NBNYC will be renamed Newtek BankTM, National Association and Newtek's current portfolio companies Newtek Business Lending, LLC and Small Business Lending, LLC will be contributed to Newtek Bank, N.A. The OCC approval is subject to the condition that Newtek Bank, N.A. enter into an operating agreement with the OCC upon the close of the Acquisition, which operating agreement contains customary provisions concerning capital, liquidity and concentration limits and memorializes the business plan submitted to the OCC. Barry Sloane, Chairman, President and Chief Executive Officer said, "We could not be more elated to receive the OCC's approval to move forward and close the Acquisition and become a bank holding company and financial holding company. With a national bank charter, we believe Newtek will be able to enhance the business and financial solutions offered to our customers to include personalized digital commercial banking and the Newtek AdvantageTM dashboard and truly become NewtekOne - the One Solution for All Your Business Needs."

08:31 EST Viveve announces issuance of U.S. method patent for treating female SUI - Viveve Medical announced the United States Patent and Trademark Office has issued U.S. Patent No. 11511110 covering Viveve's treatment to address SUI in women. The issuance of the new patent strengthens the Company's intellectual property portfolio in advance of the planned completion of its U.S. pivotal PURSUIT clinical trial by the end of the year and reporting of topline results in early 2023. Viveve's dual-energy technology has demonstrated the ability to activate fibroblasts and initiate collagen formation in tissue in a non-invasive, painless, and comfortable in-office procedure. When applied to the areas surrounding the urethra, the technology's unique mechanism of action may strengthen and improve the function of connective tissues, improve vaginal structural integrity, and reduce urethral hypermobility, a leading cause of SUI in women.

08:27 EST SOBR Safe expands SaaS agreement with Alternatives, Inc. - SOBR Safe announced that its software as a service agreement with Alternatives, Inc. has been expanded to replace breathalyzers in a second facility.

08:24 EST Orezone Gold declares commercial production at Bombore Gold Mine - Orezone Gold announced that the Bombore Gold Mine has achieved commercial production, effective December 1, 2022. Orezone has declared commercial production at Bombore based on achieving 30 consecutive days of mill throughput exceeding 70% of nominal nameplate capacity of 14,250 tonnes per day and recovery reaching design levels of 90%. During November 2022, the mill processed 364,123 ore tonnes at a recovery rate of 91%. Management plans to provide annual guidance for Bombore in January 2023.

08:23 EST Carrick Therapeutics closes $25M Series C financing - Carrick Therapeutics announced it has raised $25 million in a Series C financing. The financing round was supported by existing investors, including ARCH Venture Partners, Rosetta Capital, Lightstone Ventures, Google Ventures (GOOG, GOOGL), Cambridge Innovation Capital, and Evotec (EVO). The Company intends to use the proceeds to fund ongoing and planned samuraciclib clinical trials, ongoing development of its CDK12/13 inhibitor / Cyclin-K glue-degrader, and for working capital and general corporate purposes. Carrick has raised a total of $60 million from the Series C financing and Pfizer (PFE) investment. The Company recently announced Pfizer Inc. has made a $35 million investment in Carrick. Carrick will maintain full economic ownership and control of samuraciclib and the rest of its pipeline.

08:19 EST Mayfair reports eighth set of drilling results for 2022 from Fenn-Gib expansion - Mayfair Gold announces the eighth set of drill results for 2022 from the Fenn-Gib resource expansion and infill drill program. Mayfair's 100% controlled Fenn-Gib Project, located in the Timmins region of Northeast Ontario, hosts a NI 43-101 open-pit constrained Indicated Resource of 3.06 million ounces and an Inferred Resource of 0.31M ounces. Mayfair Gold President and CEO Patrick Evans commented: "The remarkable intercept of 1.10 g/t gold over 366.7m from near-surface in hole FG22-253 is one of the best results from our drill program and highlights the exceptional quality of the Fenn-Gib deposit. This intercept is further confirmation of the robust nature of the high-grade plunge identified on west side of the deposit. The more moderate grades reported from holes FG22-256, 258 and 260 appear to represent the limits of the mineralization on the north side of the deposit within the conceptual open pit."

08:17 EST Voip-Pal.com announces termination of all Alice 101 motions in NDCA - VoIP-Pal.com announces that Judge Donato has stayed all of the pending VoIP-Pal patent litigations in the Northern District of California, NDCA, and terminated the pending motions for judgment on the pleadings under 35 U.S.C. Section 101 without prejudice to refiling after the January 26, 2023 status conferences. The cases are Case Nos. 3:21-cv-5275, 3:21-cv-9773, 3:22-cv-3199, 3:19-cv-3202, 3:22-cv-4279, and 3:22-cv-5419. The Company also continues to litigate several cases in the U.S. District Court for the Western District of Texas, WDTX. VoIP-Pal's cases asserting the Mobile Gateway patents against Amazon.com, Inc., et al., 6:21-cv-668, Verizon Communications, Inc., et al., 6:21-cv-672, and T-Mobile USA, Inc., 6:21-cv-674 are currently nearing the end of the fact discovery phase. Additionally, the Company has appointed Howard "Clif" Saylor to the Board of Directors.

08:16 EST Otonomo Technologies delivers new fleet product enhancements - Otonomo Technologies announced a new set of fleet enablement capabilities to support fleet operators as they scale and grow their businesses. The new services available through the Otonomo Smart Mobility Data Platform enable fleet managers greater self-service and ease-of-use, resulting in a highly customized user experience, easily tailored to fleet-focused business needs. "Fleet management is a vital business function for many organizations today, from car rental businesses to fleet management companies, mobility as a service providers and beyond," said Ben Volkow, CEO and co-founder at Otonomo. "However, managing vehicle fleets is highly complex, requiring the right technology and expertise to achieve operational and business goals. Our new set of fleet capabilities deliver a competitive advantage to fleet managers as they seek out ways to streamline and optimize their fleet operations."

08:16 EST NLS Pharmaceutics receives notice of allowance for Mazindol patent from USPTO - NLS Pharmaceutics announced that the United States Patent and Trademark Office, or USPTO, has issued a Notice of Allowance for U.S. Patent Application 16/645,306, which covers Mazindol as a method of treatment for heroin dependence and substance use disorders comprising administering mazindol or composition comprising mazindol to a subject, wherein the substance is an opioid and Mazindol is administered daily at a daily dosage range from between 3 mg and 16 mg. NLS expects this patent to be issued within the next few months and it is expected to expire no earlier than 2038.

08:14 EST Vaxart announces collaborative funding for study on Novovirus vaccine candidate - Vaxart announced it will commence a new study of Vaxart's oral pill norovirus vaccine candidate focused on protecting breastfeeding mothers and their infants. The study will receive significant funding and support from the Bill & Melinda Gates Foundation. This funding follows Vaxart's previous collaboration with Duke University on a pre-clinical COVID-19 transmission study also funded by the Gates Foundation. The study will examine whether Vaxart's vaccine candidate induces antibodies in the breast milk of lactating mothers and whether infants up to 6 months of age can acquire those antibodies. Vaxart believes there are potential advantages to this approach. "By triggering mucosal immunity in addition to protecting those vaccinated, our vaccines may also reduce transmission - the key mechanism by which viral infections spread, further increasing their overall effect on the broader population. This study investigates inducing mucosal immunity at an important site that ultimately might result in positively impacting transmission," said Andrei Floroiu, Vaxart's Chief Executive Officer. "We are pleased with the funding and support from the Gates Foundation, which will help realize the potential impact of our vaccine technology on global public health."

08:13 EST Splunk announces five-year extension of collaboration agreement with AWS - Splunk (SPLK) announced a five-year extension of its strategic collaboration agreement with Amazon (AMZN) Web Services. During this week's AWS re:Invent 2022, Splunk was also named the ISV Partner of the Year in North America at the 2022 Regional and Global AWS Partner Awards and revealed a public preview of the Splunk Add-on for Amazon Security Lake.

08:12 EST Grom Social's Curiosity Ink Media, Cepia Entertainment partner for Santa.com - Grom Social Enterprises' Curiosity Ink Media's Santa.com announced the launch of the site's new Yuletide Advent Calendar, How the Gherkins Stole Christmas, based on the wildly popular Cats vs. Pickles franchise. Packed with feline fun, pickle hijinks and exciting cliffhangers, the story will roll out in 25 pickle-tastic chapters that will captivate kids and keep families laughing together as the big day approaches. The animated Christmas countdown calendar, courtesy of an exclusive partnership between Curiosity Ink Media and Cepia Entertainment, was announced by Darren Marks, Chairman and CEO of Grom Social Enterprises.

08:10 EST Integra LifeSciences plans $150M share repurchase - The company is planning a $150 million share repurchase as a part of a previous approval by the board of directors. The company may repurchase shares at its discretion, subject to applicable regulatory and other legal requirements. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions, regulatory requirements, and other corporate considerations, and could be suspended or discontinued at any time as determined by management. Commencement of share repurchases is expected to occur in early 2023 and the company may utilize various methods to make the repurchases. The benefit of the share repurchases to adjusted earnings per share is expected to largely offset the first year of earnings dilution from the acquisition of SIA.

08:09 EST Moody's to acquire SCRiesgo, terms undisclosed - Moody's announced that it has agreed to acquire SCRiesgo, a group of local credit rating agencies serving domestic financial markets in Central America and the Dominican Republic. The acquisition significantly expands Moody's presence in Latin America and reaffirms its commitment to and support for the ongoing development of regional capital markets. Following the acquisition, SCRiesgo will become an affiliate of Moody's Local, Moody's domestic credit ratings platform, with SCRiesgo continuing to issue domestic ratings with an independent analytical and rating committee process. SCRiesgo General Manager Gary Barquero will continue to lead the company's operations following the acquisition.

08:08 EST Roivant Sciences, Pfizer form new Vant company focused on developing RVT-3101 - Roivant Sciences (ROIV) and Pfizer (PFE) announced formation of a new Vant to develop and commercialize PF-06480605, now RVT-3101. The Vant has the exclusive option to collaborate with Pfizer on a next-generation TL1A directed antibody which recently entered Phase 1. RVT-3101 has been evaluated in an earlier Phase 2 study in 50 patients, and is being evaluated in a large global Phase 2b study in 245 adult participants with moderate to severe ulcerative colitis. The induction portion of TUSCANY-2 is complete, and the maintenance portion remains ongoing. "Our internally discovered antibody against TL1A, could potentially be the first agent to bring biomarker-selected precision medicine to people living with inflammatory bowel disease," said Mikael Dolsten, Pfizer's Chief Scientific Officer, President, Worldwide Research, Development and Medical. "We are very excited about the preliminary data from the TUSCANY-2 study and for this new Vant to drive the advancement of this asset." Terms of Collaboration: A new Vant or Roivant subsidiary has been created to develop and fund these programs. The Vant will be fully responsible for funding global development of RVT-3101 in UC and in additional inflammatory and fibrotic diseases and holds commercial rights in the US and Japan. Pfizer owns a 25% equity position in the Vant and maintains commercial rights outside of the US and Japan as well as representation on the company's Board of Directors. In addition, the Vant has the exclusive option to collaborate with Pfizer on a next-generation TL1A directed antibody which recently entered Phase 1. The Vant will have the right to enter into an agreement for global development with a 50/50 cost share as well as co-commercialization rights with Pfizer prior to Phase 2, expected in 2025.

08:06 EST BigCommerce announces record Cyber Week with GMV up 32% - BigCommerce reported its merchants experienced another year of record sales during Cyber Week, hitting a 32% increase in gross merchandise value, or GMV, over 2021 and exceeding what has been an overall successful five days for the retail industry. In addition to the increase in GMV, shoppers were more active from Thanksgiving to Cyber Monday this year with total orders up 25%. As expected Black Friday and Cyber Monday saw the biggest sales volumes for BigCommerce merchants during the five-day period with Cyber Monday GMV growing just over 32% compared to the same day last year. Black Friday GMV was up 31% over 2021.

08:05 EST Scynexis announces FDA approval of second indication for BREXAFEMME - SCYNEXIS announced that the U.S. Food and Drug Administration, FDA, has approved a second indication for BREXAFEMME for the reduction in the incidence of recurrent vulvovaginal candidiasis, RVVC. "We are proud to be continuous innovators in the anti-infective space, and to provide a groundbreaking antifungal treatment option proven to reduce recurrence in women suffering from repeated vaginal yeast infections," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "BREXAFEMME was already the only non-azole oral therapy available for VVC and is now the only therapy FDA-approved for both VVC and RVVC. This exciting second indication supports our mission to arm both patients and healthcare providers with innovative solutions in the fight against severe fungal infections." The approval is based on positive results from the pivotal Phase 3 CANDLE study that evaluated the safety and efficacy of monthly dosing of ibrexafungerp to reduce the incidence of RVVC. Results showed that 65.4% of patients receiving ibrexafungerp achieved clinical success by having no recurrence at all, either culture-proven, presumed, or suspected, through Week 24 compared to 53.1% of placebo-treated patients.

08:02 EST Salarius announces interim results from Phase 1/2 trial of Seclidemstat - Salarius Pharmaceuticals announces interim clinical trial results from the company's Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment for Ewing sarcoma and FET-rearranged sarcomas. These interim results appear to indicate that first- and second-relapse Ewing sarcoma patients treated with seclidemstat in combination with topotecan and cyclophosphamide who achieve disease control may have an increased time to tumor progression compared with treatment of topotecan and cyclophosphamide alone, per the Phase 3 rEECur study described below. As of October 31, 2022, 13 first- and second-relapse Ewing sarcoma patients were evaluable for confirmed disease control rate assessment. Of these 13 patients, five patients achieved confirmed disease control with no tumor progression observed while treated with seclidemstat in combination with topotecan and cyclophosphamide. Treatment duration for the 13 patients ranged from 0.7 months to 13.8 months. Five first-relapse Ewing sarcoma patients were treated and three achieved confirmed disease control, including one complete response, one partial response and one stable disease at 12.8 months and continuing. First-relapse patients had a median TTP of 7.4 months and treatment duration ranged from 1.4 months to 13.8 months. David Arthur, President and CEO of Salarius, said, "These interim results are encouraging, and I believe they show the potential for seclidemstat to provide a more durable response among Ewing sarcoma patients when used in combination with topotecan and cyclophosphamide. This trial has more than 15 clinical trial sites with more than 20 locations throughout the United States, and when needed Salarius provides travel assistance to patients who want to participate in the sarcoma trial. It is our hope that the potential for seclidemstat to improve outcomes coupled with our support will make it easier for patients to participate when enrollment is restarted."

07:52 EST Brown-Forman to name Marshall Farrer chief strategic growth officer - Brown-Forman announced that Marshall Farrer, president, Europe, will expand his leadership responsibilities and be named executive VP, chief strategic growth officer, effective January 1, 2023. In addition to stewarding Brown-Forman's European business, Farrer, in his new role as chief strategic growth officer, will work closely with Lawson Whiting, president and CEO, and the entire Brown-Forman executive leadership team, on developing key partnerships and new growth opportunities to achieve the company's short-term objectives and long-term ambitions.

07:47 EST Nutriband receives notice of issuance from CIPO for AVERSA patent - Nutriband announced that the Canadian Intellectual Property Office has granted Canadian patent No. 2,937,649, entitled "Abuse and Misuse Deterrent Transdermal Systems," with an issue date of November 1, 2022. This patent protects Nutriband's AVERSA transdermal abuse deterrent technology being developed to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential that are delivered with a transdermal patch. The issuance of this Canadian patent in combination with patents already issued in the United States and Mexico provides intellectual property protection for Nutriband's Aversa products across North America. In addition, the Aversa abuse deterrent technology is covered by a broad intellectual property portfolio with patents already granted in the United States, Europe, Japan, Korea, Russia, and Australia.

07:45 EST Goodbody Health CEO Marc Howells resigns - Goodbody Health announces that Marc Howells has resigned from the Board and as CEO with immediate effect. George Thomas, an existing Executive Director of Goodbody Health and Managing Director of Goodbody Wellness has been appointed as the new CEO, also with immediate effect.

07:40 EST Monarch reports results from 2022 drilling program on McKenzie Break project - Monarch Mining reports additional results from the 2022 drilling program on its wholly owned McKenzie Break gold project, located 25 kilometres north of the Corporation's Beacon mill with a design capacity of 750 tpd. This press release relates to newly received assay results for 12 holes, namely holes MK-22-334 to 338, MK-22-343 to 344, MK-22-352 to 354 and MK-22-356 to 357. "Our primary aim is to continue to expand the footprint of the mineral resource estimate, including the proposed pitshell," said Jean-Marc Lacoste, President and Chief Executive Officer of Monarch. "The McKenzie Break mineralization remains open in all directions, and the near-surface intersections we are seeing confirm that the current pit shell limits and underground resource can still be expanded in several directions."

07:38 EST Knight Therapeutics announces relaunch of AKYNZEO in Canada - Knight Therapeutics announced that it has assumed full commercial activities and is relaunching oral AKYNZEO in Canada. Knight and Helsinn Healthcare SA entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI oral/IV in Canada in May 2022. "We are excited to take over Canadian commercialization of AKYNZEO, an innovative once-per-cycle fixed dose, dual combination antiemetic that offers a leading and guideline-recommended prophylactic treatment for chemotherapy induced nausea and vomiting," said Samira Sakhia, President and CEO of Knight. "AKYNZEO builds upon Knight's growing Canadian oncology portfolio, increasing our presence in this important therapeutic area."

07:36 EST CTO Realty Growth announces pricing of upsized public offering of stock - CTO Realty Growth announced that it has priced an upsized underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $19.00 per share. The Company has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock. The offering is expected to close on December 5, 2022, subject to customary closing conditions. Total estimated gross proceeds of the offering are approximately $57 million or approximately $66 million if the underwriters exercise their option to purchase additional shares in full. The Company intends to use the net proceeds from this offering to fund a portion of the $96 million purchase price of its recently announced lifestyle, mixed-use acquisition opportunity it currently has under contract. If the pending acquisition is not completed for any reason, the Company intends to use the net proceeds to fund other potential acquisition opportunities and for general corporate and working capital purposes, including the repayment of debt. Wells Fargo Securities, Raymond James, BMO Capital Markets, Truist Securities and KeyBanc Capital Markets are acting as joint book-running managers for the offering. Baird, PNC Capital Markets LLC, Regions Securities LLC, Synovus Securities Inc., Compass Point, Janney Montgomery Scott, JonesTrading, B. Riley Securities and EF Hutton, division of Benchmark Investments, LLC, are acting as co-managers for the offering.

07:34 EST Oncolytics receives FDA Fast Track designation for pelareorep - Oncolytics Biotech (ONCY) announced that the U.S. FDA has granted Fast Track designation to pelareorep in combination with Roche's (RHHBY) anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma. This represents pelareorep's second FDA Fast Track designation.

07:33 EST Walgreens extends same day delivery offering to fulfill orders 24-hours a day - Walgreens is extending its same day delivery offering to fulfill orders 24-hours a day, seven days a week in markets across the country. Now, customers can order from Walgreens.com/SameDayDelivery or the Walgreens app and receive an assortment of more than 27,000 items delivered in as little as one hour, no matter the time of day. Walgreens 24-Hour same day delivery offers delivery of the most items for a 24-hour retail delivery service. The service comes to nearly 400 participating 24-hour Walgreens stores across the country and offers delivery of last-minute needs like groceries, over-the-counter medications, personal care items, household essentials and more. Customers may select the nearest 24-hour location to place their order and the order will be fulfilled if in delivery range. To celebrate the launch, Walgreens is offering customers free delivery on orders of $20+ with code NOW20 through December 10. 24-hour same day delivery is not currently available in Alaska, Colorado, Iowa, Maine, North Dakota, South Dakota, Utah, Vermont, West Virginia and Wyoming.

07:33 EST Citius Pharmaceuticals' application for denileukin diftitox approved by FDA - Citius Pharmaceuticals' Biologics License Application for denileukin diftitox, an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, has been accepted by the FDA . I/ONTAK is a purified and more bioactive formulation of previously FDA-approved ONTAK. The PDUFA target action date is September 28, 2023. The BLA is supported by a pivotal Phase 3 study.

07:31 EST Rogers Sugar expects 'strong, stable' financial performance in 2023 - The company said, "The health and safety of our employees continue to be our top priority. We will continue to monitor closely the potential impacts related to the COVID-19 pandemic and follow closely public health authority recommendations.Following a strong performance in 2022, including our highest sugar volume, consolidated revenue and adjusted EBITDA results to date, we expect to deliver a strong, stable financial performance in 2023. The continued strength in sugar demand and pricing is expected to provide stable results, despite ongoing challenges related to supply chain and logistics. We expect our Maple segment to slowly recover during 2023 as the unfavorable inflationary pressures encountered over the last year begin to recede. We expect the sugar segment to perform well in fiscal 2023. Underlying North American demand remains strong across all customer segments supported by favourable market dynamics. Improvements in pricing implemented in 2022 will continue to support our financial results positively, allowing us to mitigate the current impact of inflationary pressures on costs. We expect sales volume for 2023 to reach 790,000 metric tonnes, representing a reduction of approximately 5,000 metric tonnes as compared to 2022. The slight reduction in volume in 2023 relates to the temporary increase in volumes recorded in the later part of 2022, in connection with a temporary tightness in market supply in North America. We do not expect this tightness to reoccur and anticipate the domestic market to be otherwise stable for 2023. We expect export volumes to decrease as we will prioritize the growing domestic demand. Our current view for volume by customer segment in 2023 is as follows: Industrial, our largest segment, is expected to decrease by 3%, although demand for sugar-containing products remains steady both in Canada and the US. Liquid volume is expected to growth by 6.0 % driven by continued demand from existing customers. Consumer volume is expected to increase by 2% for 2023, due to higher expected demand. We anticipate selling 10% less to the export markets in 2023, due to the growing demand of the domestic market. We intend to explore potential supplemental export sales as favourable opportunities arise. The harvest period for our sugar beet facility in Taber was completed in early November. We have received the expected quantity of beets from the Alberta growers. However, unfavourable weather conditions such as hailstorms and warmer temperatures encountered in the later stage of the growing period have reduced the expected sugar content of the sugar beets. We are currently in the processing stage of the 2022 beet campaign. We anticipate completing the processing of the sugar beets received by the end of February. Currently, based on our early assessment, we anticipate the 2022 crop to deliver between 100,000 metric tonnes and 110,000 metric tonnes of beet sugar. This would be lower than the 2021 crop which delivered 120,000 metric tonnes. Production costs and maintenance programs for our three production facilities are expected to be moderately impacted by the current inflationary market-based pressures, as we continue to focus on cost control initiatives throughout our operations. Distribution costs are expected to be stable in 2023. These expenditures will continue to reflect the market dynamics requiring the transfer of sugar produced in the West to the East to meet customer demand. We also expect that recent cost increases for logistics and our supply chain will remain. Once our planned expansion project is completed, we plan to optimize our increased national capacity to efficiently service our domestic customer base. Administration and selling expenses are expected to decrease in 2023 as we do not anticipate the impact of share-based compensation to be as high. We have been able to mitigate the potential unfavourable impact on our business of the recent increases in interest rates and energy costs through our multi-year hedging strategy. We do not anticipate these increases to have a material impact on our financial results in the near future, as we expect our hedging strategy will continue to mitigate such risks. Spending on regular business capital projects is also expected to be stable for fiscal 2023. We anticipate spending approximately $25 million on various initiatives, with approximately a quarter allocated to return-on-investment projects. This estimate for capital spending excludes potential expenditures that could be incurred in 2023, regarding the announcement we made in August 2022, about our intention to expand the capacity of our Montreal sugar refinery and Toronto distribution centre. The Maple segment financial results were lower than anticipated for 2022. This was due mainly to lower volume and unexpected inflationary pressures on costs for packaging material, freight, and labour, along with global shipping challenges. We expect these financial and operating pressures to remain in the first part of 2023. Despite such challenges and a strong 2022 crop, we expect this business segment to slowly recover and to deliver slightly improved financial performance in 2023 as compared to 2022. The improvement will be driven by expected higher volume from new customers and higher margin from price increases on recently negotiated agreements. Capital investments have reduced significantly for the Maple segment in recent years. The Maple segment is expected to spend between $1 million and $2 million annually on capital projects. The main driver for the Maple segment projects is to improve productivity and profitability through automation."

07:25 EST Capital Power sees 2023 AFFO $805M-$865M - Operational targets: Capacity-weighted average facility availability of 94%, reflecting planned outages for Genesee 1 and 2 repowering, and other thermal facilities, Sustaining capital expenditures of $135 million to $145 million.. Financial and dividend targets: The 2023 financial targets are based on various assumptions including: 10,000 gigawatt hours of the Alberta commercial generation portfolio sold forward at an average contract price in the high-$70 per megawatt hour range, average forward Alberta spot power price of approximately $136/MWh, and forward AECO natural gas price of approximately $4.60/GJ. Adjusted EBITDA of $1,455 million to $1,515 million, AFFO of $805 million to $865 million, and Annual dividend growth guidance of 6% from 2023 to 2025 with an expected average AFFO payout of approximately 40% through 2025 compared to the 45% to 55% target range. Growth targets: Continue progress on the Genesee 1 and 2 Repowering project based on revised schedule and forecast, Advancement of Genesee CCS Project and Genesee Carbon Conversion Centre, Proceed with two renewable projects, Continued progress on Halkirk 2 on time and on budget, and Target $600 million of committed capital for growth for 2023.

07:23 EST Capital Power provides update on strategic developments - Capital Power continues to advance its Genesee CCS project with the Board of Directors approval of a LNTP for the $2.3 billion project. Progress on funding programs from the Alberta and Federal governments such as the Alberta CCS Hub initiative, Emissions Reduction Alberta support for the FEED study, the Federal CCUS Investment Tax Credit, the Canada Infrastructure Bank, the Canada Growth Fund and the Strategic Innovation Fund supported our LNTP decision. Proceeding with LNTP allows the Company to move into the next stage of final due diligence and commercial, financing and technical assessment in advance of a final investment decision expected by the third quarter of 2023 with commercial operations as early as 2027. Once operational, Genesee CCS is expected to capture up to 3 million tonnes of CO2 per year, which would be transported and stored through Enbridge's Open Access Wabamun Carbon Hub. This will position Genesee 1 and 2 amongst the cleanest baseload thermal generation facilities in the world. In action of our purpose, to power a sustainable future for people and planet, Capital Power has accelerated its net zero target to 2045 from 2050. The growing government support for CCS and other carbon reduction technologies, including direct air capture, and Capital Power's commitment to reducing its carbon footprint supported accelerating its target to achieve net zero by 2045. Progress on the Genesee 1 and 2 repowering project continues and is on schedule for the Company to meet its off-coal commitment in 2023. Genesee 1 and 2 is expected to achieve simple cycle commissioning in late 2023, followed by combined cycle commissioning in 2024. The repowering project cost has been revised to $1.1 billion compared to the $997 million budget largely due to significantly higher interconnection costs. An additional 75 MW from Clydesdale Solar, located in the Municipal District of Taber, Alberta, is expected to begin commercial operations on schedule in December 2022. The total project cost is expected to be $124 million compared to the original budget of $102 million due to Covid-related supply chain pressures and significant increases in transportation costs. The facility currently has a 15-year renewable energy agreement with Labatt Breweries of Canada for 51% of the output and expect that most of the remaining capacity will be contracted.

07:22 EST OraSure reaffirms dedication to end HIV epidemic - OraSure Technologies will ring the closing bell for the Nasdaq Stock Market this afternoon in honor of World AIDS Day. World AIDS Day is commemorated annually on December 1 to raise awareness of the AIDS epidemic and to mourn the loss of those who have died of the disease. "OraSure has played a critical role in the fight against HIV globally since 2002. For more than two decades, we have championed the importance of access to personal information about health through easy-to-use diagnostics, particularly for vulnerable communities around the world most burdened by HIV," said OraSure President and CEO Carrie Eglinton Manner. "Today we vow to continue that fight, both globally through partnership with non-governmental organizations that provide tests to low- and middle-income countries to help combat the HIV crisis, and domestically through innovative programs like the Centers for Disease Control and Preventions 'Take Me Home,' HIV self-test program."

07:21 EST Brady announces regional organizational structure effective February 1, 2023 - Brady Corporation announced it will modify its organizational structure under new regional operating segments effective February 1, 2023. Beginning in the third quarter of fiscal 2023, the Company will report sales and segment profit based on new operating segments: Americas & Asia and Europe & Australia. The Americas & Asia business will be led by Olivier Bojarski, currently the President of the Company's Identification Solutions business. The Europe & Australia business will be led by Brett Wilms, currently the Managing Director of Identification Solutions EMEA and the Interim General Manager of the Company's Workplace Safety business. "By moving to a regional structure, we are better positioning the Company for long-term success by aligning the organization with opportunities for future sales growth," said Brady's President and CEO, Russell Shaller. "This new structure will help us accelerate sales growth by taking advantage of the synergies that exist between our current divisions, by utilizing our best go-to-market strategies in each of our key geographies, and by using our increased geographic scale to accelerate new product development while delivering tailored solutions that meet the unique needs of each geography. Although cost reduction was not the primary motivator for this reorganization, we expect to realize an improvement of $0.10 to $0.20 of earnings per share beginning in fiscal 2024, and we expect that any one-time charges from employee severance in fiscal 2023 will be offset by reduced costs over the balance of this fiscal year."

07:20 EST Greenwave Technology opens 12th metal recycling facility in Fairmont, NC - Greenwave Technology Solutions announces its 12th metal recycling facility has opened in Fairmont, North Carolina, NC. With one of the largest footprints of metal recycling facilities in the mid-Atlantic region, Greenwave supplies some of the world's leading steel mills with a continuous supply of ferrous and non-ferrous metal. Additionally, Greenwave's shareholders overwhelmingly approved each of proposed corporate actions and elected the Company's existing board of directors by a wide margin. "We are grateful to Greenwave's shareholders for their unwavering support and we are committed to delivering on our aggressive growth strategy," stated Danny Meeks, Chief Executive Officer of Greenwave. "For us to open the Fairmont facility, we ultimately had to replace the roof, remodel the office, and install new scales - but believe its contribution to our metal volumes and revenue will make it well worth the hard work and long delay. In the coming weeks, we expect to open our 13th location, bring our second automotive shredder online, and release our growth plans for 2023. With the strongest balance sheet in our corporate history, we believe Greenwave is optimally positioned to create shareholder value in the coming quarters."

07:19 EST Apollo Silver reports first assay results from Phase 2 drilling - Apollo Silver reports initial assay results from the recently completed Phase 2 of the 2022 Drill Program at the Calico Silver Project located in San Bernardino County, California. "These first assay results from our Phase 2 drill program continue where Phase 1 left off," commented Apollo CEO Tom Peregoodoff. "Our primary focus for Calico in 2022 was two-fold. First, to provide additional confidence to the current resource to enable us to maximize the amount of silver ounces we can convert to a higher resource category. Second, to expand the extent of known silver mineralization. I am pleased to report that on both counts we have been successful... These initial results have also confirmed the extensive nature of the gold horizon, and while not a primary focus, the potential to add gold to the upcoming revised MRE could make a meaningful impact to the outcome of the planned 2023 Preliminary Economic Assessment."

07:17 EST Provectus announces new data from combination trial of PV-10, Keytruda - Provectus announced that new data from the Company's ongoing, multi-cohort, Phase 1b/2 study of the combination of small molecule cancer immunotherapy PV-10, an intratumoral formulation of Provectus' rose bengal sodium active pharmaceutical ingredient, and anti-PD-1 therapy Keytruda for the treatment of immune checkpoint blockade-naive Stage III cutaneous melanoma are being presented at Melanoma Bridge 2022 in Naples, Italy and online from December 1-3, 2022. Entitled "Response for combination of PV-10 autolytic immunotherapy and immune checkpoint blockade in stage III cutaneous melanoma." Key Highlights of the Melanoma Bridge 2022 Presentation: Efficacy: 50% complete response and 83% overall response rate. Rapid CRs - 2 within 15 weeks and 1 within 27 weeks. Durability: Median progression-free survival not reached during 2-year treatment interval; 83% PFS rate. All CRs ongoing after 18 to 36 months of study follow-up. Survival: Median overall survival not reached. 100% OS rate for CRs; ongoing after 18 to 36 months of study follow-up. Safety: Consistent with established patterns of PV-10 and Keytruda single-agent use. Consistent with prior PV-10 and Keytruda combination therapy cohorts of CB-naive and CB-refractory advanced melanoma patients. Mechanism of immune action: Precise, increased, PV-10-induced T-cell activity preceded CR. Similar immune upregulation observed in monotherapy PV-10 treatment of Stage III melanoma patients and PV-10 and Keytruda combination treatment of CB-refractory advanced melanoma patients. Successfully combining PV-10 and CB in Stage III melanoma patients is predicated on achieving rapid response of PV-10-injected lesions that may lead to rapid, durable CR of patients and ultimately to improved PFS and OS: Single-agent PV-10 achieved 56% CR of injected lesions in Stage III patients4, but only 23% CR of non-injected lesions, and a median PFS of 8.9 to 9.8 months 5, Single-agent CB may exhibit a similar response rate in Stage III patients to PV-10's response rate in non-injected lesions, with a median PFS of 11.7 months 6, and The combination of PV-10 and CB in CB-naive Stage IV patients has shown the potential for significant combinational interaction and durability, while also presenting a non-overlapping safety profile.

07:14 EST Regeneron's fianlimab and Libtayo featured in solid tumor presentations - Regeneron announced new and updated data across its oncology pipeline to be presented at the European Society for Medical Oncology Immuno-Oncology - ESMO IO - Congress from December 7-9 in Geneva. Presentation highlights include first clinical results and new exploratory analyses from trials investigating LAG-3 inhibitor fianlimab and/or PD-1 inhibitor Libtayo - cemiplimab - in non-small cell lung cancer, melanoma and cervical cancer. Israel Lowy, Senior VP, Translational and Clinical Sciences, Oncology at Regeneron, said: "Libtayo has already proven to be an effective immunotherapy across multiple tumor types and is poised to serve as a foundational therapy for our investigational combination approaches. Fianlimab combined with Libtayo has generated early-but-promising clinical activity in advanced melanoma and non-small cell lung cancer, demonstrating the potential of Regeneron's oncology pipeline to potentially advance the standard-of-care in various cancers." Efficacy results demonstrated an objective response rate of 27% - 4 of 15 patients -. Additionally, exploratory analyses of the naive cohort found the ORR was 50% among those who had not received any prior systemic therapy and 100% among those with tumors that had greater than or equal to 50% PD-L1 expression. Median duration of response was not reached in the naive cohort and was 5 months in the experienced cohort. Rates of greater than or equal to grade 3 adverse events were respectively 33% and 40%, while rates of serious AEs were respectively 20% and 13%. There were no treatment-related deaths reported in either cohort.

07:14 EST Charge Enterprises, GenZ EV Solutions installs first ultra-fast ChargeBox - Charge Enterprises and GenZ EV Solutions announced the installation of their first ultra-fast ChargeBox, powered by ADS-TEC Energy. The installation is at The Suburban Collection of Troy, Michigan, a Lithia Group Dealership. This installation will provide The Suburban Collection with battery buffered, ultra-fast charging technology to support the growing demand for rapid EV charging solutions. The GenZ EV ChargeBox, powered by ADS-TEC, includes 140kW/h of integrated energy storage that supplies up to 320kW of energy from the existing infrastructure. For locations that have utility demand charges, the technology allows for ultra-fast charging with as little as 50kW of input power from the grid. This technology supports both the avoidance of expensive peak demand charges and the avoidance of expensive and time-consuming utility permitting and upgrades. The ChargeBox charges one vehicle at up to 320kW, or two EVs at up to 160kW simultaneously, and supplies 100 miles charging range in less than ten minutes. Distributed by GenZ, the ChargeBox offers ultra-fast charging on existing, power-limited grids with minimal or no infrastructure or upgrades.

07:12 EST Renalytix announces highlights from publication of data on use of KidneyIntelX - Renalytix announced additional highlights from the publication of data from a clinical utility study demonstrating that use of KidneyIntelX risk assessment in the primary care setting resulted in improved clinical decision making and observed clinical outcomes for 1,686 patients in the earliest stages of diabetic kidney disease. The results published in the Journal of Primary Care and Community Health evaluated the effectiveness of a health system driven care management program focused on treating DKD patients in the earliest stages of the disease before significant loss in kidney function and other complications can develop. This study data is especially meaningful for overburdened clinical teams in the primary care community who lack accurate tools, time and resources to understand which type 2 diabetes patients are at highest risk for rapid progressive CKD decline. With KidneyIntelX risk assessment, they can adjust clinical care by optimizing medications developed to slow CKD progression, providing earlier consultation or referral to specialists, and increasing frequency of follow-up visits thereby promoting and preserving kidney function before irreversible damage occurs. The key highlights from this real-world evidence study publication include: 57% of high risk patients had action taken within 3-months, compared to 35% for low risk patients; Notably clinical observations from the study showed a nearly 10% improvement in HbA1c levels in the high risk group in the first six months. While other metrics such as eGFR and systolic blood pressure remained unchanged at the 6-month data mark, there was a 15% improvement in albuminuria, an important indicator of overall kidney health, in the low and intermediate risk groups.

07:11 EST Orchard Therapeutics announces Swissmedic Validation of MAA for Libmeldy - Orchard Therapeutics announced its marketing authorization application, MAA, for Libmeldy has been accepted for evaluation by the Swiss Agency for Therapeutic Products for the potential treatment of eligible patients with early-onset metachromatic leukodystrophy, MLD. The Swiss filing was based on the European Union, EU, MAA for Libmeldy, which was approved by the European Commission in December 2020. Libmeldy is registered in the EU, Iceland, Liechtenstein, Norway and the United Kingdom. The company expects to receive Swissmedic's assessment report in the first half of 2023. "Swissmedic's validation of the MAA is a key component of our commercial expansion efforts in Europe to secure additional approvals in countries and territories where Libmeldy is not currently authorized," said Braden Parker, chief commercial officer of Orchard Therapeutics. "We are encouraged by our continued dialogue with regulatory authorities on the safety and efficacy of this important therapy for eligible children with early-onset MLD, including the long-term clinical outcomes seen in clinical trials."

07:09 EST Moving iMage announces passing of CFO Michael Sherman - Moving iMage announced the passing of chief financial officer Michael Sherman on November 30.

07:07 EST Bitfarms mines 453 new bitcoin in November - Bitfarms provided a Bitcoin production and mining operations update for November 2022. "In November, we mined 453 BTC, bringing our year-to-date total to 4,672 BTC mined, up 51% from the same period in 2021," said Ben Gagnon, Chief Mining Officer of Bitfarms. "With new capacity coming online in Sherbrooke, our November hashrate increased 5% to 4.4 exahash/second by mid-month, compared to 4.2 EH/s at the beginning of the month. We averaged 15.1 BTC mined per day for the full month and exited November at a similar rate, down from an average of 15.7 BTC mined per day for the month of October 2022. November production was impacted primarily by increases in network difficulty and a shorter month, which has set four all-time highs in the last six adjustments. Year to date, network difficulty is up 52% while Bitfarms' hashrate has grown 109%. Our strategy of using low-cost hydro power and highly efficient miners continues to deliver stable electricity rates and consistently low production costs. As such, we believe that Bitfarms is well positioned to benefit from any industry-related curtailment, idling or shutting down of miners that may occur as a result of high fossil-fuel energy source expense."

07:05 EST Nexstar appoints Michael Strober as chief revenue officer - Nexstar announced the appointment of innovative and experienced sales and advertising executive Michael Strober as executive VP and chief revenue officer, responsible for leading the reimagination and execution of a new advertising sales and go-to-market strategy for the company. As Nexstar's diversified media portfolio has evolved into a powerful combination of national brands and reach, with the largest local broadcast station group capable of engaging local and national audiences at scale, this newly created position will enable the company to leverage its sales efforts across its linear, digital, mobile and streaming platforms to deliver new levels of revenue growth. Strober will report to Nexstar's chairman and CEO, Perry Sook, and begin his new duties January 2, 2023.

07:04 EST Compugen's COM701 shows preliminary anti-tumor activity in ovarian cancer - Compugen announced publication of abstracts by ESMO-IO showing that at the time of abstract data cutoff, Compugen's COM701 - anti-PVRIG - in dual and triple combination with nivolumab +/- BMS-986207 demonstrated preliminary anti-tumor activity and immune activation in platinum resistant ovarian cancer patients and was well tolerated. At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 demonstrated 20% overall response rate and 40% disease control rate in heavily pretreated patients with platinum resistant ovarian cancer and was well tolerated, with all responders remaining on therapy. CEO Anat Cohen-Dayag commented, "At ESMO-IO we will present encouraging preliminary anti-tumor activity supported by immune activation and favorable safety profile following the dual and triple blockade of PVRIG, PD-1 +/- TIGIT in platinum resistant ovarian cancer patients. The full data to be presented at the conference remain under embargo until December 6, 2022 and will contain longer follow up. We are looking forward to discussing this data along with our NSCLC data which will also be presented at ESMO-IO, in addition to our plans going forward, during our investor call on December 7, 2022."

07:03 EST Tonix Pharmaceuticals presents development update on TNX-801 - Tonix Pharmaceuticals announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, presented data from the Company's TNX-801 smallpox and monkeypox vaccine development program in an oral presentation at the World Vaccine and Immunotherapy Congress 2022, being held in San Diego, Calif., November 28 - December 1, 2022. "TNX-801 is a live virus vaccine that we believe is closer to the smallpox vaccines used in the U.S. and Europe before 1900 than the modern vaccinia smallpox vaccines. TNX-801 has reduced virulence in animals, and we believe it has the potential for widespread use to protect against monkeypox," said Seth Lederman, M.D., President and Chief Executive Officer. "Recent global outbreaks of monkeypox have highlighted the need to be prepared with a vaccine that provides durable immunity and blocks forward transmission. Tonix's live virus vaccine technology is designed to achieve these outcomes." The oral presentation titled, "Live Virus Smallpox and Monkeypox Vaccine," describes the history of live virus vaccines and rationale for the development of the Company's Recombinant Pox Virus platform. The presentation describes the origins of immunization, beginning with the first live virus vaccine invented by Dr. Edward Jenner in 1798. Today, molecular analysis of DNA sequences from archaic smallpox vaccines suggests that TNX-801 is closer than modern smallpox vaccinia vaccines to the vaccine discovered and disseminated by Dr. Edward Jenner6-8.

06:58 EST Nuscale Power signs collaboration agreement for clean hydrogen research - NuScale Power, along with Shell Global Solutions and industry participants, will develop and assess a concept for an economically optimized Integrated Energy System for hydrogen production using electricity and process heat from a NuScale VOYGR small modular reactor power plant. The project will be completed in two phases. Additional research participants include Idaho National Laboratory, Utah Associated Municipal Power Systems, Fuel Cell Energy, FPoliSolutions, and GSE Solutions. NuScale's flexible SMR technology aims to have the potential to balance and stabilize power grids dominated by renewable energies through hydrogen production. The research will consider the number of NuScale Power Modules needed for use in SOEC hydrogen production and the quantity of hydrogen stored for subsequent electricity production.

06:52 EST Pyxis Oncology announces FDA clearance of two IND applications - Pyxis Oncology announced that it has received clearance for its two Investigational New Drug applications from the U.S. FDA to initiate Phase 1 clinical trials. PYX-201, a novel antibody-drug conjugate product candidate, will be investigated for the potential treatment of several solid tumors, including breast, head and neck, lung, and thyroid cancer. PYX-106, an immunotherapy product candidate, will be investigated for the potential treatment of solid tumors, including bladder, cholangio-carcinoma, colorectal, and kidney cancer. Trials are expected to begin in early 2023.

06:40 EST Toronto-Dominion expects to close First Horizon deal in 1H23

06:38 EST Saia reports October LTL shipments down 4.4%, November-to-date down 8.6% - The company states: "Saia is providing LTL shipment and tonnage data for the first two months of the fourth quarter. In October 2022, final LTL shipments per workday declined 4.4%, LTL tonnage per workday declined 3.0% and LTL weight per shipment increased 1.4% to 1,445 pounds compared to 1,425 pounds in October 2021. Through November 29, 2022, LTL shipments per workday have declined 8.6%, LTL tonnage per workday has declined 7.7% and LTL weight per shipment has increased 1.0% to 1,427 pounds compared to 1,413 pounds in November 2021."

06:35 EST eGain named supplier on Crown Commercial Services' G-Cloud Framework - eGain has been approved as a supplier on Crown Commercial Service's - CCS - G-Cloud Framework. CCS supports the public sector to achieve maximum commercial value when procuring common goods and services. The UK Government G-Cloud is an initiative that aims to make it easy for UK public sector organisations to procure cloud-based IT products and services. The G-Cloud framework lists cloud-based suppliers and solution providers, which meet the UK Government's stringent requirements for privacy, security, and scalability.

06:32 EST Toronto-Dominion reports Common Equity Tier 1 Capital ratio of 16.2%

06:10 EST Wallbox appoints new Chief Communications and Public Affairs Officer, CMO - Wallbox announced two strategic hirings. The company created a new communications and public affairs team, which will be led by Myriam Lhermurier Boublil. As Chief Communications & Public Affairs Officer, Myriam will lead a team, already established in Spain and the U.S: The company hired Javier Riano, who joins Wallbox as its new Chief Marketing Officer. Myriam Lhermurier Boublil led teams in Europe, the Middle East and Asia during her career at Google. She also led PayPal's international communications department for more than 3 years, before moving to Barcelona in 2021 to join Domestika as Senior VP of Global Communications. Javier Riano previously acted as vice president of corporate marketing for Spain and director of beauty and grooming for southern Europe at Procter & Gamble. Previously, Javier Riano has worked in different roles within the field of marketing, brand communication and e-commerce at Procter & Gamble on an international level, in cities such as Barcelona, Madrid, Rome and Geneva.

06:06 EST Big Lots sees Q4 comparable store sales down in low double-digit range - The company said, "For the fourth quarter, the company expects comps to be down in the low-double-digit range. Net new stores will add about 170 basis points of growth versus 2021. The company expects the fourth quarter gross margin rate to improve sequentially versus Q3 but remain in the mid-30s range. This includes the impact of additional markdowns related to accelerated store closures and continued efforts to clean up slow-moving inventory. Given an atypically wide range of outcomes, the company is not providing EPS guidance at this point. The company expects a share count of approximately 29.0 million for Q4."

06:01 EST Greenwich LifeSciences extends lock-up of directors, officers to end of 2023 - Greenwich LifeSciences announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to December 31, 2023 which is approximately 39 months from date of the company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the company's common stock unless otherwise modified by the Board of Directors.

05:32 EST STMicroelectronics, Soitec announce next stage of SiC substrates cooperation - STMicroelectronics and Soitec announced the next stage of their cooperation on Silicon Carbide, or SiC, substrates, with the qualification of Soitec's SiC substrate technology by ST planned over the next 18 months. The goal of this cooperation is the adoption by ST of Soitec's SmartSiC technology for its future 200mm substrate manufacturing, feeding its devices and modules manufacturing business, with volume production expected in the midterm.

05:18 EST Li Auto delivers 15,034 vehicles in November, up 11.5% - Li Auto announced that the company delivered 15,034 vehicles in November, achieving record-high monthly deliveries and representing a 11.5% year-over-year increase. The cumulative deliveries of Li Auto vehicles reached 236,101 as of the end of November.

05:14 EST NIO Inc. delivers 14,178 vehicles in November, up 30.3% - Nio (NIO) announced its November delivery results. Nio delivered 14,178 vehicles in November, a new record-high monthly delivery, representing an increase of 30.3% year-over-year. The deliveries consisted of 8,003 premium smart electric SUVs including 4,897 ES7s, and 6,175 premium smart electric sedans including 3,207 ET7s and 2,968 ET5s. Cumulative deliveries of Nio vehicles reached 273,741 as of November 30. Nio will further accelerate the production and delivery in December. On November 28, NIO and Tencent (TCEHY) entered into a strategic cooperation agreement to further deepen partnership in the areas of autonomous driving related cloud services, intelligent driving maps and digital ecosystem to provide users with experiences beyond expectation.